Janet F Eary1, Ernest U Conrad1, Janet O'Sullivan2, Douglas S Hawkins3, Scott M Schuetze4, Finbarr O'Sullivan2. 1. University of Washington, UWMC Box 356113, Seattle, WA 98195. E-mail address for J.F. Eary: jeary@UW.edu. E-mail address for E.U. Conrad: ernest.conrad@seattlechildrens.org. 2. School of Mathematical Sciences, University College Cork, Western Gateway Building, Western Road, Cork, Ireland. E-mail address for J. O'Sullivan: janet.osullivan@ucc.ie. E-mail address for F. O'Sullivan: f.osullivan@ucc.ie. 3. Department of Hematology and Oncology, Seattle Children's Hospital, B 6553, 4800 Sand Point Way, Seattle, WA 98105. E-mail address: doug.hawkins@seattlechildrens.org. 4. Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan Cancer Center, 1500 East Medical Center Drive, SPC 5912, Ann Arbor, MI 48109. E-mail address: scotschu@med.umich.edu.
Abstract
BACKGROUND: Our previous research investigated the ability of [F-18]fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging results to predict outcome in patients with sarcoma. Tumor uptake of FDG before and after neoadjuvant chemotherapy was predictive of patient outcome. With this background, a prospective clinical study was designed to assess whether tumor FDG uptake levels in the middle of neoadjuvant chemotherapy added additional prognostic information to pre-therapy imaging data. METHODS: Sixty-five patients with either bone or soft-tissue sarcoma were treated with neoadjuvant-based chemotherapy according to the standard clinical practice for each tumor group. All patients had FDG PET studies before therapy, mid-therapy (after two cycles of chemotherapy), and before resection. Tumor FDG uptake (SUVmax, the maximum standardized uptake value) at each imaging time point, tumor type (bone or soft-tissue sarcoma), tumor size, and histopathologic grade were recorded for each patient. The time from the pre-therapy FDG PET study to events of local tumor recurrence, metastasis, or death were extracted from the clinical records for comparison with the imaging data. Univariate and multivariate analyses of the imaging and clinical data were performed. RESULTS: Univariate and multivariate data analyses showed that the difference (measured as the percentage reduction) between the pre-therapy and mid-therapy maximum tumor uptake values added prognostic value to patient outcome predictions independently of other patient variables. CONCLUSIONS: The utility of a tumor pre-therapy FDG PET scan as a biomarker for the outcome of patients with sarcoma was strengthened by a mid-therapy scan to evaluate the interim treatment response.
BACKGROUND: Our previous research investigated the ability of [F-18]fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging results to predict outcome in patients with sarcoma. Tumor uptake of FDG before and after neoadjuvant chemotherapy was predictive of patient outcome. With this background, a prospective clinical study was designed to assess whether tumorFDG uptake levels in the middle of neoadjuvant chemotherapy added additional prognostic information to pre-therapy imaging data. METHODS: Sixty-five patients with either bone or soft-tissue sarcoma were treated with neoadjuvant-based chemotherapy according to the standard clinical practice for each tumor group. All patients had FDG PET studies before therapy, mid-therapy (after two cycles of chemotherapy), and before resection. TumorFDG uptake (SUVmax, the maximum standardized uptake value) at each imaging time point, tumor type (bone or soft-tissue sarcoma), tumor size, and histopathologic grade were recorded for each patient. The time from the pre-therapy FDG PET study to events of local tumor recurrence, metastasis, or death were extracted from the clinical records for comparison with the imaging data. Univariate and multivariate analyses of the imaging and clinical data were performed. RESULTS: Univariate and multivariate data analyses showed that the difference (measured as the percentage reduction) between the pre-therapy and mid-therapy maximum tumor uptake values added prognostic value to patient outcome predictions independently of other patient variables. CONCLUSIONS: The utility of a tumor pre-therapy FDG PET scan as a biomarker for the outcome of patients with sarcoma was strengthened by a mid-therapy scan to evaluate the interim treatment response.
Authors: Matthias R Benz; Johannes Czernin; Martin S Allen-Auerbach; William D Tap; Sarah M Dry; David Elashoff; Kira Chow; Vladimir Evilevitch; Jeff J Eckardt; Michael E Phelps; Wolfgang A Weber; Fritz C Eilber Journal: Clin Cancer Res Date: 2009-04-07 Impact factor: 12.531
Authors: Gi Jeong Cheon; Min Suk Kim; Jun Ah Lee; Soo-Yong Lee; Wan Hyeong Cho; Won Seok Song; Jae-Soo Koh; Ji Young Yoo; Dong Hyun Oh; Duk Seop Shin; Dae-Geun Jeon Journal: J Nucl Med Date: 2009-08-18 Impact factor: 10.057
Authors: Andrei Iagaru; Rinat Masamed; Sant P Chawla; Lawrence R Menendez; Alex Fedenko; Peter S Conti Journal: Clin Nucl Med Date: 2008-01 Impact factor: 7.794
Authors: Vladimir Evilevitch; Wolfgang A Weber; William D Tap; Martin Allen-Auerbach; Kira Chow; Scott D Nelson; Fredrick R Eilber; Jeffery J Eckardt; Robert M Elashoff; Michael E Phelps; Johannes Czernin; Fritz C Eilber Journal: Clin Cancer Res Date: 2008-02-01 Impact factor: 12.531
Authors: Donald A Podoloff; Ranjana H Advani; Craig Allred; Al B Benson; Elizabeth Brown; Harold J Burstein; Robert W Carlson; R Edward Coleman; Myron S Czuczman; Dominique Delbeke; Stephen B Edge; David S Ettinger; Frederic W Grannis; Bruce E Hillner; John M Hoffman; Krystyna Kiel; Ritsuko Komaki; Steven M Larson; David A Mankoff; Kenneth E Rosenzweig; John M Skibber; Joachim Yahalom; Jq Michael Yu; Andrew D Zelenetz Journal: J Natl Compr Canc Netw Date: 2007-05 Impact factor: 11.908
Authors: Matthew J Thompson; John C Shapton; Stephanie E Punt; Christopher N Johnson; Ernest U Conrad Journal: Clin Orthop Relat Res Date: 2018-03 Impact factor: 4.176
Authors: Amani Arthur; Edward W Johnston; Jessica M Winfield; Matthew D Blackledge; Robin L Jones; Paul H Huang; Christina Messiou Journal: Front Oncol Date: 2022-07-01 Impact factor: 5.738
Authors: Douglas J Harrison; Yueh-Yun Chi; Jing Tian; Pooja Hingorani; Leo Mascarenhas; Geoffrey B McCowage; Brenda J Weigel; Rajkumar Venkatramani; Suzanne L Wolden; Torunn I Yock; David A Rodeberg; Andrea A Hayes-Jordan; Lisa A Teot; Sheri L Spunt; William H Meyer; Douglas S Hawkins; Barry L Shulkin; Marguerite T Parisi Journal: Cancer Med Date: 2020-12-19 Impact factor: 4.452